TABLE 165Mixed-treatment comparison – MMSE at 12–13 weeks (mean change from baseline; OC populations): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo0.001
Donepezil1.2220.468 to 1.9880.9970.505
Galantamine0.469−1.487 to 2.4490.7040.149
Rivastigmine1.0790.075 to 2.1440.9800.346
Memantine

From: Appendix 9, Mixed-treatment comparisons performed in specified measurement populations

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.